Elmind Capital’s Cogent Biosciences COGT Stock Holding History

Elmind Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.3M	Hold	1,170,740	–	–	11.38%	1
2026 Q1	$45.1M	Hold	1,170,740	–	–	12.79%	1
2025 Q4	$41.6M	Buy	+1,170,740	New	+$32.9M	12.27%	1

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Elmind Capital's COGT Position: Q2 2026 in Review

Elmind Capital held its Cogent Biosciences (COGT) position steady in Q2 2026 at 1,170,740 shares worth $45.3M. The position accounts for 11.38% of the portfolio, ranked #1.

Elmind Capital first reported a position in COGT in Q4 2025 and has held it in 3 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Elmind Capital held 1,170,740 shares of Cogent Biosciences worth $45.3M as of Q2 2026.
Elmind Capital left its Cogent Biosciences share count unchanged in Q2 2026.
Cogent Biosciences made up 11.38% of Elmind Capital's portfolio in Q2 2026, its #1 holding.
Elmind Capital first reported a position in Cogent Biosciences in Q4 2025 and has held it in 3 quarters since.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.